Ultrasound vendors faced intense competition during the secondquarter of this year. Diasonics reported that pricing pressureskept its ultrasound business in the red for the second quarter(end-June). Ultrasound revenue remained at about the same levelas
Ultrasound vendors faced intense competition during the secondquarter of this year. Diasonics reported that pricing pressureskept its ultrasound business in the red for the second quarter(end-June). Ultrasound revenue remained at about the same levelas the first quarter of 1991, the vendor said.
Overall, however, Diasonics had a 17% jump in revenue, from$59.5 million in the second quarter of 1990 to $69.5 million inthe same period this year. Net income from continuing operationsfor the quarter rose 16%, from $4.3 million in 1990 to $5 millionin 1991.
Westmark International's net income for the second quarterof 1991 (also end-June) was halved from $5.3 million in 1990 to$2.2 million. Overall revenues declined 10.5% from $126 millionin the second quarter of 1990 to $114.2 million in the same periodof this year. Spacelabs, Westmark's patient monitoring company,had an 11% growth in revenue, while sales at ultrasound subsidiaryATL dipped 23%.
The decline in ATL's ultrasound business resulted from shipmentof non-revenue units during the introduction of its high-definitionimaging (HDI) upgrade to the Ultramark 9 scanner, an increasein backlog for the UM9, and a drop in shipments of low- and mid-tiersystems, Westmark said.
The picture was brighter for Acuson. The dedicated high-endultrasound vendor saw both net sales and net income rise 18% duringthe same quarter. Sales rose to $82.7 million from $70.2 millionin the second quarter of 1990. Net income jumped from $11.8 millionin the second quarter of last year to $14.4 million during thesame period of 1991.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Ultrasound-Guided Thermal Ablation Shows Low Recurrence of Thyroid Carcinoma at Five Years
June 16th 2025In a meta-analysis involving over 2,200 patients with T1NoMo papillary thyroid carcinoma, researchers noted 2 percent recurrence and no cases of lymph node metastasis five years after ultrasound-guided thermal ablation.